Data Editor, Pharma
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From John Hodgson
The end-of-year stock valuations across Big Pharma jumped nearly 3% in December led by financial reassurances at Valeant and gleeful shareholder reaction to ceremonial employee sacrifices at Teva.
This year's Scrip 100 collection is bigger than ever, encompassing 2016 full-year financial data from more than 650 biopharmaceutical companies.
Bellwethers tell you something, but to gauge the health of the pharmaceutical industry, you really need the Scrip 100. For FY 2016, it looks like drug sales are up again and profits are down. But is this what's actually going on?
Spending on R&D increased substantially in 2016; but the picture is complicated and more than half of the increase is due to accountancy updates following drug program failures, one large company's commitment to new projects, and young companies fuelled by generous financial markets.
Generic drug producers endured very mixed fortunes on the world's stock markets, with firms ending November at opposite ends of Scrip's Stock Scan monthly league table.
Pharma stocks suffered in October, particularly in North America. Across the globe, stock prices among the biggest pharmaceutical companies were down an average of 2% on the month, despite general market revivals in Asia. The generics sector was particularly badly hit but there were several major setbacks for branded pharma companies, too.